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Ethical and Regulatory Challenges with Autologous Adult Stem Cells:  
A Comparative Review of International Regulations 
 
 
INTRODUCTION 
 
Over the last decade, the use of human cell and tissue-based products (CTPs) in new and innovative 
therapies  has  drawn  increasing  interest  from  healthcare  providers,  researchers,  patients,  and 
regulators,  internationally.  However,  despite  there  being  few  accepted  clinical  uses,
1 CTPs are 
increasingly being prescribed for conditions that have not been demonstrated as safe or effective in 
clinical trials. In particular, autologous adult stem cells (ASCs) are being offered directly to patients, 
typically over the Internet, for a wide range of diseases and conditions for which there is insufficient 
evidence that demonstrates their safety and efficacy.
2 While evidence has emerged in recent years 
to reduce initial safety fears about the tumour -forming properties of ASCs, clinical data that 
supports the efficacy of these products for many indications has been either limited to early Phase 
I/II trials, or in some cases, non-existent.
3  
 
Until recently, these practices were utilized mainly by patients trave lling from wealthy nations to 
low-to-middle income countries, or so-called ‘stem cell tourism’.
4 These countries, including China, 
Thailand, and India,
5 were assumed to foster stem cell clinics because they lacked the necessary 
regulatory infrastructure to monitor and control the practices of clinics and healthcare institutions 
operating within their jurisdiction.
6 This picture is, however, no longer adequate, as autologous ASCs 
are increasingly being offered in wealthy countries, such as the United States,  Japan and Australia.
7 
This means both that patients need no longer travel long distances to access ‘unproven’ cellular 
therapies and that the global escalation of these practices cannot be simply explained as a matter of 
poor or weak regulation in emerging economies. 
 
                                                 
1    George Q Daley, "The Promise and Perils of Stem Cell Therapeutics," Cell stem cell 10, no. 6 (2012). 
2    Alan C. Regenberg et al., "Medicine on the Fringe: Stem Cell-Based Interventions in Advance of Evidence," 
Stem Cells 27, no. 9 (2009); Darren Lau et al., "Stem Cell Clinics Online: The Direct-to-Consumer Portrayal 
of Stem Cell Medicine," Cell Stem Cell 3, no. 6 (2008). 
3    Carl Power and John E Rasko, "Promises and Challenges of Stem Cell Research for Regenerative Medicine," 
Annals of Internal Medicine 155, no. 10 (2011). 
4    Use of this label to describe  the complexity of marketing stem cells direct to patients has been criticized 
elsewhere. Tamra Lysaght and Doug Sipp, "Dislodging the Direct to Consumer Marketing of Stem Cell -
Based Interventions from Medical Tourism," in Bodies across Borders: The Global Circulation of Body Parts, 
Medical Tourists and Professionals, ed. Brownwyn Parry, et al. (Ashgate Press, 2014). 
5    Regenberg et al., "Medicine on the Fringe: Stem Cell-Based Interventions in Advance of Evidence."; Lau et 
al., "Stem Cell Clinics Online: The Direct-to-Consumer Portrayal of Stem Cell Medicine." 
6    Sorapop Kiatpongsan and Douglas Sipp, "Offshore Stem Cell Treatments,"  Nature  Reports  Stem  Cells  
(2008). 
7    Tamra  Lysaght  et  al.,  "Oversight  for  Clinical  Use s  of  Autologous  Adult  Stem  Cells:  Lessons  from 
International Regulations," Cell Stem Cell 13, no. 6 (2013). ARI Working Paper No. 232  Asia Research Institute ● Singapore 
 
 
 
4 
 
In  a  study  funded  by the  Ethical  and  Social  Research Council in  the United Kingdom,  Petra  and 
Sleeboom-Falkner describe how disparities in regulatory systems across geographical contexts are 
being exploited by what they term as ‘bionetworks’
8. These networks are represented by loosely 
organized transnational relationships between physicians, science entrepreneurs, researchers and 
patients, who operate mostly, although not exclusively, within the private healthcare sector.
9 They 
work in part by exploiting differences and inequalities in the provision of healthcare, standards of 
wealth, capacity to conduct scientific research, and regulatory infrastructure between rich and 
poor(er) countries. While this study provides some evidence of bionetwork s extending out of Asia 
and into the highly protected markets of the so -called  ‘West’,  most  notably  through  patient 
recruitment,
10 their infiltration into high income countries with lucrative domestic markets for novel 
therapeutics has not been uniform nor  has it been essential for the global proliferation of clinics 
offering autologous ASCs outside clinical trials.  
 
The global reach of bionetworks is most clearly visible in the recent events in Texas, where the 
Governor Rick Perry was administered with autologous ASCs processed using technology imported 
from the Seoul-based company formerly known as RNL Bio (it is now operating as K -STEMCELL).
11  
This intervention followed a similar procedure that had been carried out on Perry’s physician at a 
clinic  associated  with  RNL  Bio  in  Japan,
 12 where  more  than  20  clinics  are  reportedly  offering 
autologous ASCs.
13 Yet, in Australia, where a sharp increase in such clinics has occurred following the 
introduction of a new regulatory framework for CTPs,
14 the connections with bionetworks in Asia or 
elsewhere are less visible. Furthermore, other countries such as Singapore, Canada and the United 
Kingdom, have been relatively successful in controlling the use of autologous ASCs within their 
borders. Hence, there are likely diff erences in regulatory systems amongst  wealthy nations with 
similar  standards  in  healthcare,  scientific  investment  and  economic  structure  that  may  be 
encouraging or discouraging the provision of autologous ASCs to patients outside clinical trials.  
 
This paper examines the regulatory systems of five geographically diverse but socio-economically 
comparable countries with the aim of identifying similarities and differences in how novel uses of 
CTPs  are  regulated  and  governed  within  clinical  contexts.  We  follow  this  examination  with  a 
discussion about the strengths and weaknesses of these approaches and suggest ways in which 
international governance may better achieve a balance between the need to protect vulnerable 
patient populations and the desire to enable scientific and clinical innovation. 
 
                                                 
8    Prasanna Kumar Patra and Margaret Sleeboom-Faulkner, "Bionetworking: Experimental Stem Cell Therapy 
and Patient Recruitment in India," Anthropology & Medicine 16, no. 2 (2009). 
9   Margaret Sleeboom-Faulkner and Prasanna Kumar Patra, "Experimental Stem Cell Therapy: Biohierarchies 
and Bionetworking in Japan and India," Social Studies of Science 41, no. 5 (2011). 
10   Patra and Sleeboom-Faulkner, "Bionetworking: Experimental Stem Cell Therapy and Patient Recruitment 
in India." 
11   Tamra Lysaght et al., "Global Bionetworks and Challenges in Regulating A utologous Adult Stem Cells," 
American Journal of Medicine 126, no. 11 (2013). 
12   Susan  Berfield,  "Stem  Cell  Showdown:  Celltex  Vs.  The  Fda,"    Businessweek  (2013), 
http://www.businessweek.com/articles/2013-01-03/stem-cell-showdown-celltex-vs-dot-the-fda  
13   Akira Akabayashi and Misao Fujita, "The Present and Future of St em Cell Therapy in Japan" (paper 
presented at the Ethics for the Future of Life: Proceedings of the 2012 Uehiro -Carnegie-Oxford Ethics 
Conference, 2012). 
14   Megan Munsie and Martin  Pera, "Regulatory Loophole Enables Unproven Autologous Cell Therapies to 
Thrive in Australia," Stem Cells and Development in print (2014).  ARI Working Paper No. 232  Asia Research Institute ● Singapore 
 
 
 
5 
 
COMPARATIVE REVIEW OF INTERNATIONAL REGULATORY APPROACHES TO CTPs 
 
The five countries selected for the comparative review – Australia, Japan, Singapore, the UK, and the 
USA  –  were  chosen  from  the  extant  literature  because  of  their  comparability  across  key 
socioeconomic and health indicators. They are all structured as capital markets and are among the 
46 countries classified by the World Bank as high-income economies.
15 They each spend between 1.7 
and 3.4% of gross domestic product a year in research and development
16 and have comparably high 
capacities for scientific research.
17 While different healthcare systems are in place, the standards of 
healthcare offered to patients are relatively stable across these jurisdictions.
18 These countries have 
also invested heavily in biomedicine and medical biotechnologies, including regenerative medicines 
based on stem cells and other CTPs. 
 
To support these investments, these countries have all established regulatory infrastructure to 
enable the protection of intellectual property rights and govern research involving human subjects. 
Regulations for human subject research in each country are based on internationally -accepted 
standards initially set in the Nuremberg Code and later adopted b y the World Medical Association 
(WMA) in the Declaration of Helsinki
19 and the Council for International Organizations of Medical 
Sciences (CIOMS) for the International Ethical Guidelines for Biomedical Research Involving Human 
Subjects.
20 These standards outline basic imperatives for informed consent, voluntariness, privacy, 
confidentiality and independent oversight from an Institutional Review Board (IRB) or an equivalent 
body. Most have also established frameworks for research involving human stem cells an d tissues. 
Specific laws, regulations and guidelines adopted in each country for human subject and stem cell 
research are extensive, of which some are shown in Table 1. 
                                                 
15   World  Bank  (2012),  List  of  Economies,  Available  at  http://data.worldbank.org/about/country-
classifications/country-and-lending-groups#High_income (Accessed 17 June 2013). 
16   World  Bank  (2008),  Research  and  development  expenditure  (%  of  GDP),  Available  at 
http://data.worldbank.org/indicator/GB.XPD.RSDV.GD.ZS (Accessed 17 June 2013). 
17   IMH  (2013),  World  Competitiveness  Online,  Available  at  https://www-worldcompetitiveness-com 
(Accessed 17 June 2013). 
18   IMH  (2013),  World  Competitiveness  Online,  Ava ilable  at  https://www-worldcompetitiveness-com 
(Accessed 17 June 2013). 
19   Available at http://www.wma.net/en/30publications/10policies/b3/ (Accessed 17 June 2013). 
20   Available at http://www.cioms.ch/publications/layout_guide2002.pdf (Accessed 17 June 2013). ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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Table 1: Regulatory Mechanisms for Human Subject and Stem Cell Research 
 
Jurisdiction   Administrating Body   Laws & Regulations   Guidelines  
United States   Environmental Protection Agency, 
Program in Human Research Ethics  
Title 40 Code of Federal Regulations Part 26 
Subpart A: The Common Rule  
   
    Food and Drug Administration,  
Center for Biologics Evaluation and 
Research  
Research on Transplantation of Fetal Tissue.  
Public Law 103-43  
Application of Current Statutory Authorities to Human 
Somatic Cell Therapy Products and Gene Therapy Products. 
October 14, 1993. 58 FR 53248  
    National Academy of Sciences       Guidelines for Human Embryonic Stem Cell Research (2005, 
amended 2007, 2008 & 2010)  
    National Institutes of Health       Guidelines on Human Stem Cell Research (2009)   
Human Embryonic Stem Cell Registry (2009)  
United 
Kingdom  
European Commission   Directive 2004/23/EC on Setting Standards of 
Quality and Safety for the Donation, 
Procurement, Testing, Processing, Preservation, 
Storage, and Distribution of Human Tissues and 
Cells  
   
    Council of Europe, Bioethics Division   Convention on Human Rights and Biomedicine 
(Convention of Oviedo), Articles 18, ETS No. 164 
(1997)  
Additional Protocol on Prohibition of Human 
Cloning, ETS No. 168 (1998):  
Additional Protocol to the Convention on Human Rights and 
Biomedicine concerning Biomedical Research, CETS No. 195 
(2005)  
Additional Protocol Concerning Biomedical Research, CETS 
No. 195  
    European Group on Ethics in  
Science and New Technologies  
    Ethical Aspects of Human Tissue Banking (1998)  
    Department of Health       The Use of Human Organs and Tissue: An Interim Statement 
(2003)  
    Economic and Social Research Council       Research Ethics Framework  
    Human Fertilisation and Embryology 
Authority  
Human Fertilisation and Embryology Act (1990)  
Human Fertilisation and Embryology  
(Research Purposes) Regulation (2001)  
   ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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Australia   National Health and Medical Research 
Council, Australian  
National Health and Medical Research Council 
Act (1992) and Regulations (2006)  
National Statement on Ethical Conduct in Human Research 
(2007)  
Health Ethics Committee and the 
Embryo Research Licensing 
Committee  
Prohibition of Human Cloning Act (2008)  
Research Involving Human Embryos Regulations 
(2003)  
Research Involving Human Embryos Act (2008)  
Australian Code for the Responsible Conduct of Research 
(2007)  
Ethical Guidelines on the Use of Assisted Reproductive 
Technology in Clinical Practice and Research (2007)  
Japan   Ministry of Health, Labor, and 
Welfare  
Act on Regulation of Human Cloning Techniques 
(2000) 
Rules for Enforcement of Act on Regulation of 
Human Cloning Techniques (2009)  
Ethical Guidelines for Clinical Research (2008)  
On Research and Development Utilizing Human Tissues 
Removed by Surgery and Other  Procedures (1998)  
Guidelines for Clinical Research Using Human Stem Cells 
(2006)  
    Ministry of Education, Culture, Sports, 
Science, and Technology  
    Guidelines for Handling of a Specified Embryo (2009)  
Guidelines for Derivation and Distribution of Human 
Embryonic Stem Cells (2009)  
Guidelines for Utilization of Human Embryonic Stem Cells 
(2009)  
Singapore   Ministry of Health   Medical (Therapy, Education, and Research) Act 
(1973)  
Human Cloning and Other Prohibited Practices 
Act (2004)  
Governance Framework for Human Biomedical Research 
(2007)  
Code of Ethical Practice in Human Biomedical Research 
(2009)  
    Ministry of Health National Medical 
Ethics Committee  
    Ethical Guidelines on Research Involving Human Subjects  
    Bioethics Advisory Committee       Report on Research Involving Human Subjects: Guidelines 
for IRBs  
Report on Human Tissue Research (2002)  
Report on Human-Animal Combinations in Stem-Cell 
Research (2010)  
Report on Ethical, Legal and Social Issues in Human Stem 
Cell Research, Reproductive and Therapeutic Cloning (2002)  
Report on Donation of Human Eggs for Research (2008)  
Source: Office for Human Research Protections, U.S. Department of Health and Human Services (2013)  ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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While the five jurisdictions employ different regulatory mechanisms to control the use of human 
embryos  in  research,  they  all  generally  provide  relatively  permissive  environments  for  stem  cell 
research.
21 All countries except the USA have specific legislation that prohibits the use of human 
cloning techniques for reproductive purposes. Australia and the UK have formal licensing systems in 
place that allows the creation of cloned human embryos and destruction of embryos surplus to 
infertility treatments for research purposes. This research may also be conducted in Japan and 
Singapore, at least theoretically, with approval from the releva nt authorities. Human embryonic 
stem cell (ESC) research in the USA is controlled indirectly through restrictions placed on funding 
granted through the National Institutes of Health (NIH). These restrictions were recently relaxed
22 
but, in any case, do not apply to research conducted without federal funds.  
 
In addition, all five countries have established regulatory frameworks for the sale of medicinal drugs 
and  governance  of  medical  practice.  As  the  following  analysis  indicates,  there  are  technical 
differences in how these regulations are implemented. However, there are also broad similarities 
with the general approach taken in each juri sdiction that do not lead to simple explanations as to 
why the use of autologous ASCs appears more prevalent in some countries and not others. In the 
following, we describe these regulations focusing on provisions specific to autologous uses of ASCs 
within both formal clinical trials and the practice of medicine. 
 
 
United States 
 
In the USA, the Food and Drug Administration (FDA) has jurisdiction over medicinal drugs, devices 
and  biologics  that  are  entered  into  interstate  commerce,  meaning  that  products  (or  products 
composed of ingredients) that are shipped interstate fall under the federal regulatory authority.
23 
The FDA controls entry of these products into the market through requirements for premarket 
testing of safety and efficacy in specified indication s, which usually involves a series of registered 
multiphase (I–III) clinical trials that are conducted after the sponsor obtains an Investigational New 
Drug (IND) designation. Subsequent market authorisation may include additional requirements for 
post-market surveillance.  
 
Regulation of CTPs is administered by the Center for Biologics Evaluation and Research (CBER) Office 
of Cellular, Tissue, and Gene Therapies (OCTGT) within the FDA, and depending on their specific 
formulation,  may  be  classified  as  devices,  drugs,  and/or  biologics.  CTPs  are  then  subdivided 
according to criteria set out in the Code of Federal Regulations (CFR) that are intended to establish 
whether the product is: 1) more than minimally manipulated;
24 2) intended for non-homologous use; 
3) combined with other articles; or, 4) if not for autologous use, either exerts systemic effects or 
relies on metabolic activity.
25 If a CTP meets any of these definitions, it is categorized under section 
                                                 
21   Donald Chalmers, "Stem Cell Technology: From Research Regulation to Clinical Applications," in Contested 
Cells: Global Perspectives on the Stem Cell Debate, ed. Benjamin Capps and Alistair Campbell (London: 
Imperial College Press, 2010). 
22   Constance Holden, "A First Step in Relaxing Restrictions on Stem Cell Research,"  Science 323, no. 5920 
(2009). 
23   Compliance  Policy  Guides  Section  100.200  FDA  Jurisdiction  Over  Products  Composed  of  Interstate 
Ingredients 
24   Defined  as  “processing  that  does  not  alter  the  relevant  biological  characteristics  of  cells”  in  21  CFR 
1271.3(f)(2), revised 2012 
25   21 CRF 1271.10 a(1-4)  ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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351 of the Public Health Services (PHS) Act (1944) and regulated as a biological drug according to the 
CFR. This categorisation requires pre-market authorisation from CBER and compliance with Good 
Manufacturing  Practices  (GMPs).  However,  CTPs  that  do  not  meet  any  of  these  definitions  are 
regulated solely under Section 361 of the PHS Act as “361 products”, which do not require the pre-
market evaluation required for 351 products.  
 
While  the  processing of 361  products  should  comply  with  Current  Good  Tissue  Practice  (CGTP) 
standards intended to prevent contamination by the spread of communicable diseases,
26 their use 
within clinical contexts, along with ‘off-label’ uses of approved 351 products, constitutes a medical 
procedure that lies outside the FDA’s jurisdiction. Medical procedures are instead governed within 
the practice of medicine by medical boards and civil statutes in each of the 50 American states. In 
2012, the Texas Medical Board introduced rules on the investigational use of human stem cells that 
appears to provide an alternative to the IND pathway by allowing physicians to seek IRB approval to 
prescribe  agents  not  approved  by  the  FDA  in  their  practice.
 27 Despite  these  rules,  federal  laws 
pertaining  to  manufacturing  standards  supersede  state  laws  and  they  are  unlikely  to  provide 
protection against legal action taken by the FDA in asserting its authority over CTPs that fall within 
its jurisdiction.   
 
Indeed, the FDA has exerted its authority over the manufacturing of autologous ASCs processed on-
site for non-homologous uses in the District Court of Columbia, which broadly upheld the FDA’s 
interpretation of CTPs that are entered into interstate commence as defined in CFR 1271.
28 The FDA 
has also issued a warning letter to a storage facility in Texas over violations of GMP standards for 
adipose-derived  stem  c ells.  In  addition,  the  Federal  Bureau  of  Investigation  has  successfully 
prosecuted the owner of laboratory in Arizona for unlawfully introducing allogeneic cord blood cells 
into interstate commerce while investigations into other related cases of mail frau d involving stem 
cells continue.
29 Civil action has also been initiated against the American subsidiary of  RNL Bio, RNL 
Biostar, for allegedly providing misleading information about the efficacy of their autologous ASC 
product.
30 The outcomes of these lawsui ts, and their impact on the availability of ASCs outside 
clinical trials, remain to be seen. 
 
                                                 
26   Center for Biologics Evaluation and Research (2011). Guidance for Industry: Current Good Tissue Practice 
(CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-
Based Products (HCT/Ps). Available at 
http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guida
nces/tissue/ucm285223.pdf Accessed June 4, 2013.  
27   Texas  Medical  Board  Rules  22  TAC  §§198.1 –198.3,  available  online  at 
http://www.tmb.state.tx.us/rules/docs/Board_Rules_Effective_07_04-and-08_2012.pdf.  Accessed  18 
June 2013.  
28   A number of key issues addressed in this case included the extension of the definition of “drug” to include 
cellular products, procedural issues surrounding the inclusion of autologous cells within the scope of 351 
products, and whether the transplantation of autologous cells that are processed onsite can be construed 
as interstate commerce. While the Court found in favour of the FDA, the case remains under appeal. See 
United States of America v. Regenerative Sciences, LLC et al., Civil Action No. 2010-1327 (RMC) US District 
Court DC (2012).  
29   Ewen  Callaway,  "American  Scientist  Arrested  in  Stem -Cell  Clinic  Sting,"  Nature  News  Blog, 
http://blogs.nature.com/news/2011/12/american-scientist-arrested-in-stem-cell-clinic-sting.html.  
30   David  Cyranoski,  "Patients  Seek  Stem -Cell  Compensation,"  Nature  News  Blog, 
http://blogs.nature.com/news/2012/07/patients-seek-stem-cell-compensation.html. ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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Japan 
 
Japan has a pre-market evaluation process for drugs and devices that is similar to the US FDA system. 
In such cases, market approval is generally provided by the Ministry of Health, Labour and Welfare 
(MHLW) under powers conferred by the Pharmaceutical Affairs Law (PAL) following the evaluation 
of  data  from  clinical  trials  that  demonstrates  safety  and  efficacy.  While  the  MHLW  can,  and 
sometimes does, conduct the review for approving clinical trials and granting marketing approval, 
the Pharmaceuticals and Medical Device Agency (PMDA)  – an administrative agency established 
under the MHLW – usually carries out this function.
31 In practice, requests and notificati ons are 
generally submitted to the PMDA, which reviews the submission and reports its opinion to MHLW, 
which either grants approval or makes further recommendations.  
 
Under the PAL, CTPs may be classified as ‘drugs’ if their action is pharmacological or ‘devices’ if their 
action is structural or physical. However, only those derived from processed human cells and tissues 
are  regulated  under  the  PAL.  This  includes  CTPs  that  are  expanded  ex-vivo,  treated 
pharmacologically  for  activation,  biologically-altered,  combined  with  scaffolds  or  genetically 
modified.
32 By contrast, unprocessed CTPs
33 are not regulated under the PAL. Their use presumably 
falls within the practice of medicine, which is regulated by the Medical Practitioners Law (MPL) 
(1948).
34  
 
The  MPL,  wh ich  the  MHLW  also  administers,  considers  a  practitioners’  act  of  producing  an 
unapproved drug and administering it to a patient as falling within the scope of ‘physician discretion’ 
in medical practice. CTPs that are administered in this context are therefore not governed by the 
PAL,
35 and practitioners need not seek prior approval from the MHLW/PMDA when acting within this 
zone  of  discretion.  If  the  CTP  is  being  administered  in  the  context  of  clinical  research,  as 
distinguished from a clinical trial (chiken), then practitioners are expected only to observe the 2003 
Ethical Guideline on Clinical Research, and if using stem cells, the Guidelines on Clinical Research 
Using Human Stem Cells (2006 Guidelines) will also apply. These Guidelines apply to any research 
using  stem  cells,  including  autologous  ASCs,  conducted  outside  the  formal  PAL  clinical  trial 
framework.
36 Such studies are subject to the same evaluation for safety and ethical requirements as 
a formal clinical trial, except that it is the MHLW rather than the PMDA that conducts the review.  
 
                                                 
31   Article 14.2., paragraph 1 and Article 80.3., paragraph 1, Pharmaceutical Affairs Law 
32   Guidelines on Ensuring Quality and Safety of Products Derived from Processed Cell/Tissue (PFSB/MHLW 
Notifications, 2008. 
33   Ibid. Includes the separation of tissue, mincing of tissue, separation of cells, isolation of specified cells, 
treatment by antibiotics, rinsing, sterilisation by gamma-rays etc., freezing and thawing.  
34   Act No. 201 of 1948.  
35   Article 17, Medical Practitioners Law. 
36   They do not apply to the PAL clinical trials. Paragraph 3, Scope: The present guidelines cover human stem 
cell clinical research intended to study the transplantation or administration of human stem cells, etc. into 
the human body for the t reatment of medical conditions outlined in Chapter 4. However the following 
cases are not covered by these guidelines: (1) General medical practices of established safety and efficacy. 
(2) Clinical trials conducted under the Pharmaceutical Affairs Law (1960 Law 145).  ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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Although research using stem cells that are obtained by ‘minimal manipulation’ are excluded from 
these Guidelines and thus do require approval from the MHLW.
37  
 
In addition, the MHLW has issued the  Practice Notice: Regarding the Practice of Regenerative and 
Cell Therapy with Autologous Cells and Tissue in Medical Institutions (2010). According to this Notice, 
medical institutions that intend to implement medicines using autologous stem cells need only seek 
approval from an IRB. Interventions that are classified as advanced medical therapy, which excludes 
cosmetic and preventative medicines, should advance into clinical trials for regulatory approval and 
application of insurance. However, administrative guidance documents such as this do not have the 
force of law, and compliance is merely voluntary.  
 
On 20 November, 2013, the Japanese Diet enacted the Regenerative Medicine Law (2013) along with 
revisions to the PAL. These new laws aim to simplify and speed-up the approval process for new 
regenerative medicine products, particularly stem cells. Sponsors of CTPs will now be able to receive 
marketing approval after providing only limited data regarding safety and efficacy, and without the 
need  to  conduct  three  phases  of  formal  clinical  trials.  Post-marketing  surveillance  will  then  be 
conducted for between five and seven years to further evaluate a product’s safety and efficacy.
38 In 
addition,  companies  will  be  permitted  to  use  data  from  clinical  research  conducted  at  medical 
institutions to demonstrate the safety of their products.
39 It is not yet clear if or how these reforms 
will affect the operation of the MPL. 
 
Australia 
 
In Australia, CTPs are regulated federally by the Therapeutic Goods Administration (TGA) under the 
Therapeutic Goods Act (1989) according to a recently implemented framework for biologics.
40 This 
framework categorises CTPs as either being: 1) regulated as therapeutic goods, but not as biological 
goods; 2) regulated as biological goods under the biologicals fram ework; and 3) not regulated as 
biological goods (excluded from regulation).
41   The first category  includes biological prescription 
medicines,  such  as  vaccines,  blood,  plasma  derivatives,  and  cryopreserved  haematopoietic 
progenitor cells that are used for ha ematopoietic reconstitution. These products are listed as 
medicinal products on the Australian Register of Therapeutic Goods (ARTG) following pre-marketing 
assessments of safety and efficacy in clinical trials in a manner broadly similar to the approval 
processes for drugs in the USA and Japan.  
 
                                                 
37   ‘Minimal manipulation’ is defined as the “manipulation of cells in ways that do not affect their inherent 
biological  properties,  such  as  tissue  isolation,  tissue  sectioning,  isolation  of  human  stem  cells  or 
differentiated  cells,  treatment  with  antibiotics,  washing,  sterilization  by  gamma  rays  or  other  means, 
freezing and thawing”. Stem cells collected from human fetuses (including dead fetuses)  are also not 
covered under these Guidelines. In addition, the 2006 Guidelines state that human embryonic stem cells 
shall not be used in clinical research until such standards have been established for the clinical research 
use of human embryos. 
38   D. Cyranoski, “Japan to offer fast-track approval path for stem cell therapies,” Nature Medicine 19, 510 
(2013).  
39   Y. Kobayashi, “Regenerative medicine firms to benefit from new rules,” Yomiuri Shimbun May 30, 2013.  
40   A. E. Trickett and D. M. Wall, "Regulation of Cellular Therapy in Australia," Pathology 43, no. 6 (2011). 
41   Part 3-2A of the Therapeutic Goods Act 1989 defines biologics as“a thing made from, or that contains, 
human cells or human tissues and  that is used to treat or prevent disease, ailment, defect or injury; 
diagnose a condition of a person; alter the physiological processes of a person; test the susceptibility of a 
person to disease; or replace or modify a person’s body parts”  ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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The second category of products are regulated as biologics and include human stem cells, tissue-
based  products,  such  as  skin  and  bone,  genetically  modified  and in  vitro  expanded  cell-based 
products, and combined cell and tissue products. These products are classified according to a risk-
based  framework  detailed  in  the  Australian  Regulatory  Guidelines  for  Biologicals,  which  applies 
oversight  measures  based  on  the  degree  of  manipulation  or  alteration,  and  the  intended  use 
(non/homogeneous,  autologous/allogeneic)  of  the  CTPs.  These  four  classes  are  summarised  in 
Figure 1.  
 
Figure 1: Four Classes of Biological Products Rregulated by the Australian TGA 
 
Class   Risk   Description   Requirements  
1   Very Low   Products manufactured under 
medical supervision  
A statement of compliance & entry on 
ATGR but product dossier  
2   Low   Minimally manipulated, 
homologous use  
Entry on ATGR, GMP compliance and 
product dossier  
3   Medium   More than minimally manipulated, 
non/homologous use  
Same as Class 2, but product dossier 
must include safety & efficacy data  
4   High   Highly manipulated, 
non/homologous use  
Same as Class 3 with highest level of 
safety & efficacy assessment  
 
 
All CPTs regulated as biologics under this framework must be entered onto the ARTG following a 
pre-market  approval  process,  although  assessments  of  safety  and  efficacy  data  only  apply  to 
products that are more than minimally manipulated in Classes 3 and 4. Manufacturers of products in 
Classes  2,  3, &  4 must  also  obtain  a  license  from the  TGA  that  demonstrates  compliance with 
principles equivalent to the Australian Code of Good Manufacturing Practice (GMP) for human blood 
and tissues. Very low risk products in Class 1 require only a statement of compliance with these 
standards. At the time of writing, no products had been listed in this class.  
 
Products exempt from both of these categories are not regulated as biological or therapeutic goods. 
Under the Therapeutic Goods (Excluded Goods) Order No. 1 of 2011, these products include fresh 
viable  human  organs  and  haematopoietic  progenitor  cells  for  the  purpose  of  haematopoietic 
reconstitution, reproductive tissue for use in assisted reproductive therapy, and most controversially, 
CTPs that are collected from a patient who is under the clinical care and treatment of a registered 
medical practitioner, and manufactured by that practitioner, or under the professional supervision 
of that practitioner. In this case, the CTPs must be used in the treatment of a “single indication and 
in a single course of treatment of that patient by the same medical practitioner, or by a person or 
persons under the professional supervision of the same medical practitioner”.
42  
 
The TGA has provided additional guidance of the exclusion order, which specifies that the CTPs must 
be for autologous use, that a single medical practitioner must assume responsibility for the clinical 
care of that patient, and where the practitioner is not directly involved in the manufacture of the 
CTP, that there be a “specified relationship with the agent/agency that meets the requirements for 
professional supervision.”
 43  The use of CTPs that are excluded from TGA regulation would thus fall 
within under the jurisdiction of the Medical Board of Australia and practitioners would have to 
                                                 
42   Section 4q, Therapeutic Goods (Excluded Goods) Order No. 1 of 2011 
43   Excluded Goods Order No. 1 of 2011: Guideline for Items 4(o), 4(p), 4(q) and 4(r) ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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comply with guidance contained in the Good Medical Practice: A Code of Conduct for Doctors in 
Australia. Practitioners are also required to observe federal laws pertaining to the use of advertising, 
as  breaches  may  incur  prosecution  from  the  Australian  Health  Practitioner  Regulation  Agency 
(AHPRA). No such prosecutions have been reported for offenses relating to misleading or deceptive 
advertisements of CTPs in Australia.  
 
Singapore 
 
Singapore does not have specific legislation to regulate CTPs, although they broadly fall within the 
scope of The Medicines Act (1975, revised 1985). This Act provides laws for the manufacturing, 
distribution and marketing of medicinal products, defined as “any substance or article (not being an 
instrument, apparatus or appliance) which is manufactured, sold, imported or exported for use 
wholly or mainly *…+ for a medicinal purpose”.
44 CTPs are not explicitly included in this definition, but 
nor are biologics, which the Health Sciences Authority (HSA) defines in its guidance for registering 
medicinal  products,  as  “products  derived  from  biological  systems”,  including  whole  cells  or 
organisms, or parts thereof.
 45  Manufactures of unlicensed products that fall within this definition 
are required to apply for a New Drug Application through the HSA, similar to an IND in the US, which 
is  assessed  following  the  submission  of  clinical  documents  demonstrating  safety  and  efficacy, 
according to the Medicines (Clinical Trials) Regulations (1978, revised 2000). 
 
The Medicines Act provides for exceptions to these regulations. Restrictions on the sale, supply and 
manufacturing  of  medicinal  products  that  are  set  out  in  Act  do  not  apply  to  “the  preparation, 
dispensing and assembly of any medicinal product by or under the supervision of a practitioner for 
the purpose of administration to a patient or animal under his care”
46. Thus, as biological medicinal 
products, the Act would not apply to the manufacturing, sale or use of CTPs within hospitals and 
medical  clinics.  The  Act  also  “does  not  apply  to  products  categorised  and  regulated  as  health 
products under the Health Products Act.
47 Currently though, the  Health Products Act (2007) only 
regulates product categories that have been specified in the First Schedule, which is thus far limited 
to medical devices and cosmetic products,
48 and do not include CTPs.
49  
 
The HSA has proposed to add CTPs to the First Schedule and are currently drafting regulations to 
regulate CTPs as health products. The proposed framework resembles the risk -based classification 
system used in Australia.
50 If adopted in Singapore, it is unclear how CTPs may be used in hospitals 
as the Health Products Act does not include exemptions for products that are manufactured by or 
                                                 
44   Medicines Act (1975) Part 1 Section 3(1) 
45   Guidance on Medicinal Product Registration in Singapore (2011) 
46   Medicines Act (1975) Part 2 Section 7(4) 
47   Medicines Act (1975) Part 7 Section (77) 
48   Health Products Act (2007) Part 1 Section 4(1) 
49   Medical  devices  are  defined  in  the  Schedule  as  “any  instrument,  apparatus,  implement,  machine, 
appliance, implant, in vitro reagent or calibrator, software, material or other similar or related article” and 
cosmetic products are “any substance or preparation that is intended by its manufacturer to be placed in 
contact with the various external parts of the human body or with the teeth or the mucous membranes of 
the oral cavity”. Thus, while a point-of-care cell processing device may fall within the scope of the Act, the 
cells processed using this technology would not. 
50   Ong, L.L. (2013), Regulation of human cell- and tissue-based therapeutic products in Singapore. Presented 
to the  Regulatory  Session  I:  Regulations  Around  the  World  at  the  19th  International  Society  for  Cell 
Therapy Annual Meeting in Auckland, New Zealand 22-25 April 2013.  ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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under  the  supervision  of  medical  practitioners.  CTPs  that  are  processed  and  stored  for  human 
transplantation  in  hospitals  and  medical clinics  are covered  under  the Guidelines for Healthcare 
Institutions Providing Tissue Banking (2003).
51 This guidance includes “all constituent parts of the 
human  body,  including  surgical  residues”  but  excludes  solid  organs,  placenta,  blood  and  blood 
products, and reproductive tissues,
 52 and does not include tissues that have been “processed in such 
a manner that their functional, structural and biological characteristics have been altered”.
 53 These 
products are classified as biologics, which currently fall under the Medicines Act. 
 
The legal ambiguity may have encouraged a small number of physicians to market stem cells in 
Singapore without prior approval from the HSA. While these physicians had not clearly broken any 
laws, the Singapore Medical Council (SMC) has taken disciplinary action against three practitioners 
offering CTPs outside clinical trials: Drs Georgia Lee and Low Chai Ling in 2007, for offering aesthetic 
treatments with stem cell ‘extracts’ without evidence of efficacy;
54 Dr Martin Huang Hsiang Shui in 
2009, for offering therapies involving the injection of xenogenic (animal) foetal cells into patients for 
anti-ageing and rejuvenation purposes;
55 and Dr Wong Yoke  Meng in 2010, for offering stem cell -
based ‘anti-aging’ products and therapies that were not medically proven.
56  All three doctors were 
charged with professional misconduct, issued with fines and censured, but not removed from the 
medical register. However, in 2012, the Singapore Court of Appeals overturned the SMC’s verdict 
against Dr Low on grounds that there were no established or official standards for the practice of 
aesthetic medicine at the time of the Discipline Committee’s inquiry to substantiate a charge of 
professional misconduct.
57 No claims have surfaced around the use of autologous ASCs.   
 
United Kingdom 
 
The  UK  has  also  adopted  a  risk-based  approach  although  it  differs  slightly  from  the  other 
jurisdictions; partly due to its status within the European Union. In EU countries such as the UK, CTPs 
are regulated as ‘advanced therapy medicinal products’ (ATPM) under a national framework that 
integrates  the  regulations  and  directives  of  the  European  Commission:  this  includes  the  Tissue 
Framework  Directive  (2004/23/EC),  the  ATPM  Regulation  (EC  No  1394/2007)  and  the  ATPM 
Directive  (2001/83/EC).  According  to  ATMP  Regulation,  a  centralised  authorisation  procedure 
applies to ATMPs that are intended to be marketed within the European Union. This procedure 
requires approval from the European Medicines Agency (EMA) following review of the safety and 
efficacy data. This data is initially reviewed by the EMA’s Committee for Advanced Therapies (CAT), 
which has the discretion to determine the extent and quality of the non-clinical and clinical data to 
be included in the marketing authorisation application as well as conduct of follow-up efficacy, 
                                                 
51   Regulation 4 of the Private Hospitals and Medical Clinics Regulations (1991, amended 2002) 
52   Guidelines for Healthcare Institutions Providing Tissue Banking (2003) Section 1.1a 
53   Guidelines for Healthcare Institutions Providing Tissue Banking (2003) Section 1.1b 
54   Low Chia Ling v Singapore Medical Council (2012) SGHC 191 High Court Originating Summons No 18 of 
2012. 
55   Singapore Medical Council (2009), Disciplinary Inquiry Against Dr Martin Huang Hsiang Shui. August 2009.  
56   Singapore Medical Council (2010), Disciplinary Inquiry Against Dr Wong Yoke Meng. September 2010.  
57   Low Chai Ling v Singapore Medical Council (2012) SGHC 191 High Court Originating Summons No 18 of 
2012. The SMC has since withdrawn the charges against the owner of clinic in question, Dr Lee and her 
employee Dr Low.  ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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pharmacovigilance and risk-management systems.
58 The CAT then makes recommendations to the 
Committee for Medicinal Products for Human Use (CHMP) for final approval.  
 
The supervisory authority for UK manufacturers or importers of centrally authorised ATMPs is the 
Medicines and Healthcare Products Regulatory Agency (MHRA). The MHRA defines CTPs according 
to the ATMP Directive, which may be classified as a gene therapy product, a somatic cell therapy 
product and/or an engineered tissue product.
59 However, the classification of somatic cell therapies 
only includes products that are substantially manipulated for use in the treatm ent, prevention or 
diagnosis of a disease through the “pharmacological, immunological or metabolic action of its cells 
or  tissues”.
60 Thus,  ASCs  that  are  not  substantially  manipulated  are  excluded  from  the  ATMP 
Regulations,
61 and if used an autologous graft  “within the same surgical procedure and without 
being  subjected  to  any  banking  process”,  are  also  excluded  from  regulation  under  the  Tissue 
Framework Directive.
62 Further exemptions are provided under ‘Hospital Use’ scheme of the AMTP 
Directive, which allows for the ‘non-routine’ use of any AMTP for an individual patient
63. 
 
Similar to Singapore, the Medicines Act (1968) provides additional exceptions for medicinal products 
that  are  manufactured  under  the  supervision  of  a  registered  medical  practitioner.
64 The  UK 
framework also provides a ‘specials’ scheme, which allows for the manufacture and importation of 
unlicensed medicinal products.
65 The purpose of this scheme is to ensure that patients are able to 
access medicines that the MHRA has not approved for marke ting. Thus, with permission of the 
MHRA, holders of a specials license may supply an unapproved CTP to practitioners and pharmacies 
regardless of their intended use, although the procurement and processing of such products may 
still fall under purview of t he Tissues Framework Directive and the prescribing physician must 
conform to accepted ethical standards which place the interests of patients before commercial 
imperatives.
66  
 
Outside the formal regulatory framework for CTPs, the conduct of registered practitioners in the UK 
is governed under the practice codes and guidelines of the British General Medical Council (GMC). 
Empowered under the  Medical  Act  1983,  the  GMC  has  the  authority  to  place  sanctions  on 
practitioners and remove those from the register who’s fitness to practice is found to be impaired. In 
                                                 
58   Committee  for  Advanced  Therapies.  Overview  EC  No  1394/2007.  Available  at 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000126.jsp&
mid=WC0b01ac05800292a5 Accessed 19 June 2013. 
59   Directive 2001/83/EC  
60   Ibid Part 4 Paragraph 2.2 
61   Non-substantial manipulation includes cutting, grinding, shaping, centrifugation, soaking in antibiotic or 
antimicrobial solutions, sterilization, irradiation, cell separation, concentration or purification, filtering, 
lyophilisation, freezing, cryopreservation and vitrification. EC Regulation No 1394/2007 Annex I 
62   Directive 2004/23/EC Paragraph 8 
63   AMTP Directive 2001/83/EC Article 3(7)  
64   The Medicines Act 1968 Section 9(1) 
65   As enabled under the  Medicines Act 1968  and the Human Medicines Regulations 2012 [SI 2 012/1916]. 
Specific guidance for this scheme is currently under review.  
66   Department of Health (2010). Trading Medicines for Human Use: Shortages and Supply Chain Obligations. 
Available at 
http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/gr
oups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_123637.pdf  Accessed 19 June 2013.  ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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2010, the GMC deregistered Dr Robert Trossel following an investigation by the Fitness to Practice 
Panel for unjustifiably administering an allogeneic cellular preparation (also found to contain bovine 
neural cells) to patients affected by multiple sclerosis at a clinic in Rotterdam.
67 The Panel stated 
that  the  interventions  were  based  on  “anecdotal  and  aspirational  information”,  and  called  his 
actions  “unjustifiable”  and  “exploitative”,  and  "repeated  and  serious"  breaches  of  many  of  the 
"essential tenets" of good medical practice. However, no investigations have been initiated against 
practitioners prescribing autologous ASCs outside of the accepted standard of care. 
 
 
DISCUSSION 
 
Subtle  differences  can  be  seen  in  both  the  technical  language  and  structure  of  the  regulatory 
instruments that govern experimental and clinical uses of CTPs in the five jurisdictions examined. Yet, 
the general approach is the same: each country is attempting to regulate clinical practice so that it is 
evidence-based and works in the best interests of both the nation and the people who require care. 
At the same time, the regulations still aim to provide sufficient clinical freedom such that innovation 
can be pursued by clinicians and researchers, and that interventions that lack the level of evidence 
necessary for licensing or subsidization may still be accessible to patients – particularly those with 
life-threatening illness and with few other therapeutic options. While these are laudable aims and 
the approach may support research, it also creates a number regulatory weaknesses or loopholes 
that may be exploited by commercial interests and transnational bionetworks.  
 
Structural Weaknesses in the Regulation of Research and Practice with CTPs 
 
Each of the countries examined in our analysis attempt to provide a clear evidence-based pathway 
for  CTPs  that  are  regulated  as  medicinal  drugs  while  allowing  patients  to  access  low-risk 
interventions with autologous ASCs under the supervision of their treating physicians. This general 
approach is designed to provide the necessary protections for research subjects while maintaining 
professional and patient autonomy. To support this goal, all five jurisdictions have implemented, or 
planning to in the case of Singapore, a risk-based approach to the regulation of CTPs. This approach 
gives regulators some flexibility in determining the level of oversight and standards of evidence that 
should apply before these products are introduced into clinical settings.  
 
Autologous ASCs that are sourced from an individual patient and transplanted back into that patient 
are generally regarded as representing a relatively lower risk than allogeneic products. Details about 
the level of manipulation and intended use of the cells vary slightly across jurisdiction, but there is a 
general  consensus  that  these  products  do  not  pose  serious  safety  threats  and  are  subject  to 
relatively limited regulatory oversight. Where cells are highly manipulated and there is less certainty 
about the potential risks to patients, and regulatory requirements impose greater oversight before 
they are introduced into the wider market. These cells are also treated as biological drugs and 
sponsors are required to obtain an investigational license and demonstrate evidence of safety and 
efficacy in registered clinical trials.  
 
Yet, even in these instances, there is regulatory flexibility and patients may have access to CTPs that 
have not been approved for marketing. All jurisdictions have special programs that allow patients in 
exceptional  circumstances  to  access  unapproved  medicinal  drugs.  The  programs  differ  in  name 
                                                 
67   Fitness to Practice Panel; 11 January-5 March 2010; 27 March 2010; 10-11 April 2010; 6 – 10 & 27 – 29 
September 2010; Regent’s Place, 350 Euston Road, London, NW1 3JN; Name of Respondent Doctor: Dr 
Robert  Theodore  Henri  Kees  Trossel.  (Accessed  6  May  2013,  at 
http://www.casewatch.org/foreign/trossel/sanction.pdf) ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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slightly and some of the conditions vary (for example, in the USA, the experimental agent must be 
the subject of an active IND, and in Japan the drug must be approved in the exporting country, 
whereas there are no such restrictions in Australia and the UK
68), but the basic premise is the same – 
to ensure that patients can access drugs that might save or significantly improve their quality of life 
on compassionate or humanitarian grounds. This same premise applies in principle to autologous 
ASCs. Europe, for example, has already enabled transplantation of artificial tracheas engineered 
from the stem cells of patients outside clinical trials with special permissions from the regulators.
69  
 
Further to these exceptional circumstances, all of the jurisdictions (excluding the USA) have laws 
that  explicitly  allow  the  manufacture  of  any  medicinal  drug,  including  biologics,  under  the 
supervision of a registered practitioner within hospitals, by licensed external vendors or imported 
internationally for local uses.  In the USA, the manufacturing of medicinal drugs, including CTPs, is 
controlled where products, or the ingredients that made up those product s, are shipped across 
interstate borders. The FDA’s authority over CTPs made with ingredients sourced entirely within 
state borders is unclear.
70 The United States, therefore, appears to be the most strictly regulated 
jurisdiction, despite the reports of ph ysicians prescribing autologous ASCs that the FDA has not 
approved for marketing. 
 
In  considering  how  these  discrepant  practices  occur,  it  is  important  to  realize  that  medical 
procedures  fall  within  the  practice  of  medicine,  which  is  regulated  under  separate  governance 
frameworks in all jurisdictions. Thus, the act of prescribing a registered drug or CTP for indications 
that have not been approved (i.e. ‘off-license or ‘off-label’) falls outside of the jurisdiction of the 
regulatory  authorities.  While  practitioners,  healthcare  institutions  or  manufacturers  are  not 
permitted to market or advertise the drug or CTP for any indication that has not received pre-market 
approval,  physicians  may  lawfully  prescribe  them  within  the  discretion  of  their  professional 
judgment. Where interventions do not fall within the accepted standard of care, then practitioners 
generally  need  adequate  justification  and  may  require  special  permission  from  an  institutions’ 
clinical practice, clinical governance or ethics board. In contrast, if interventions are prescribed as 
part of a research protocol, then they will generally need to be approved by an IRB (expect in the US, 
where the Common Rule is only mandated for research supported with federal funds). However, no 
permission or oversight is required from the authorities that regulate the marketing of medicinal 
products in any of these jurisdictions.  
 
                                                 
68   See the Expanded Access Program in the US at  
http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/AccesstoInvestigationalDrugs/ucm
176098.htm; the Named Patients Access program in Japan; the Special Access Scheme in Australia at 
http://www.tga.gov.au/hp/access-sas.htm; the UK Specials Scheme at 
http://www.mhra.gov.uk/Howweregulate/Medicines/Doesmyproductneedalicence/Medicinesthatdonotn
eedalicence/index.htm and the Hospital Exemption Scheme at http://www.mhra.gov.uk/home/groups/es-
policy/documents/publication/con065623.pdf. Singapore does not have a formal program, but the 
regulator has the discretion to apply similar arrangements; see  
http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/safety_information/product_sa
fety_alerts/2008/update_on_aprotinin.html  
69   Anthony P Hollander, "A Case Study of Experimental Stem Cell Therapy and the Risks of over -Regulation," 
in Contested Cells: Global Perspectives on the Stem Cell Debate, ed. Benjamin Capps and Alistair Campbell 
(London: Imperial College Press, 2010). 
70   Wiliam T Koustas and John R Fleder, "Fda Continues Efforts to Expand Power over Intrastate Commerce,"  
FDA Law Blog, http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2011/10/fda -continues-efforts-
to-expand-power-over-intrastate-commerce.html. ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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Other medical procedures that generally fall outside the control of the regulators typically include 
human organ transplants, haematopoietic stem cell transplants using autologous grafts or allogeneic 
tissues obtained from a relative within two degrees of separation, and human reproductive tissues 
that  are  used  for  in  vitro  fertilisation  and  other  artificial  reproductive  technologies.  They  also 
generally exclude procedures with autologous ASCs that have not been manipulated extensively or 
combined with other articles and are intended for use in functionally compatible tissues. There are, 
however,  important  differences  in  the  terms  used  to  describe  low-risk  products  as  ‘minimally 
manipulated’ or ‘non-substantially manipulated’. The processes that characterize minimal or non-
substantial manipulation are made explicit in Australia, the UK and Japan, while the USA uses a 
definition that reflects whether the basic characteristics of the cells are altered in the process. This 
approach provides the FDA with greater flexibility, and thus control, over CTPs that fall within its 
jurisdiction. However, because the definition is vague, it is more open to interpretation, and thus 
challenge, by practitioners who want to offer autologous ASCs without going down the IND pathway.   
 
 
CONCLUSIONS 
 
Our analysis does not explain why autologous ASCs are being prescribed outside clinical trials more 
often  in  Australia,  Japan  and  the  US,  than  in  Singapore  and  the  UK.  While  there  are  technical 
differences  and  ambiguities  in  the  language  and  implementation  of  respective  regulatory 
instruments, the general approach in each country is the same – regulating clinical practice so that it 
is evidence-based while still allowing enough freedom for clinicians and research to innovate with 
new interventions and autonomy for patients to access low risk CTPs that lack the level of evidence 
necessary for marketing or subsidization from public and private health insurers. Indeed, across all 
five jurisdictions, regulators and policymakers are generally reluctant to interfere in decisions that 
many would argue should remain in the private world of the doctor and their patient; leaving the 
clinical space largely free from external supervision. However, while this is historically, culturally and 
socio-politically  acceptable,  few  would  agree  that  physicians  should  be  allowed  to  prescribe 
whatever  they  want  without  being  accountable  to  their  patients  or  to  the  social  and  political 
systems that ultimately pay for the provision of their healthcare.  
 
The challenge in implementing these risk-based approaches is that the contexts that create scientific 
research and clinical medicine, and the characteristics of their practices, are frequently incompatible. 
The  standards  of  evidence  required  to  conduct  clinical  research  differ  greatly  from  what 
practitioners need to make clinical decisions. Scientific methodology is characterized by uncertainty 
and researchers design protocols to test hypotheses that have inherently uncertain outcomes. The 
uncertainty that underlies this methodology provides the ethical justification for conducting clinical 
research in the first place. For example, clinical equipoise, or the presence of genuine uncertainty,
71 
provides justification for randomization, and trials may be designed to terminate once an acceptable 
level of certainty is reached regarding the question under study. Clinicians, on the other hand, need 
proof, and the presence of uncertainty and disagreement within the professional community about 
treatment options must allow physicians the freedom to exercise clinical judgments.
72  
 
                                                 
71   B Freedman, "Equipoise and the Ethics of Clinical Research," New England Journal of Medicine 317, no. 3 
(1987). 
72   P B Miller and C Weijer, "Rehabilitating Equipoise," Kennedy Institute of Ethics Journal 13, no. 2 (2003). ARI Working Paper No. 232  Asia Research Institute ● Singapore 
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Balancing the demands of research with professional and patient autonomy in regulation may thus 
create a potentially intractable problem. Whereas uncertainty is a key characteristic of science, and 
regulations, ethical guidelines and governance processes can be designed to minimize harms that 
may arise from it, regulating clinical decisions in the face of uncertainty is, in many ways, much more 
difficult. However, regulators do have power to control unethical and illicit clinical practices, and a 
number of mechanisms may be used to control the use of autologous ASCs outside clinical trials. All 
five countries have torts laws in place for medical negligence and consumer protection laws that 
restrict false advertising and the provision of misleading information in medical practice. The two 
countries that have been most successful in limiting unethical practices with autologous ASCs – the 
UK  and  Singapore  –  have  also  activated  respective  medical  licensing  boards  into  action  against 
offending  practitioners.  Even  though  the  practitioners  in  question  had  been  offering  allogeneic 
products, their sanctioning, and particularly the deregistration of one, Robert Trossel, would have 
undoubtedly sent a stern warning to other practitioners considering offering unproven interventions 
with any stem cell-based product outside clinical trials.  
 
While these measures may, at least in part, explain why the prescription of autologous ASCs outside 
clinical trials appears less prevalent in Singapore and the UK than elsewhere, additional steps may be 
necessary  to  balance  the  conflicting  demands  of  research  and  practice,  and  control  unethical 
practices with stem cells. For a start, clearer guidance is needed for clinicians who want to prescribe 
low-risk interventions with autologous ASCs responsibly and access higher-risk CTPs before they 
have been approved for marketing. Special access schemes are already in place for these purposes, 
however,  to  whom  these  provisions  may  apply  and  who  should  have  access  to  specific  cell 
populations  needs  to  be  clarified.  Further  clarification  is  also  needed  on  who  should  pay  for 
interventions that have not been approved for marketing or demonstrated as safe and effective as 
costs for such treatments are generally not reimbursable under public or private health insurance 
providers.  The  types  of  skills  and  expertise  required  for  the  isolation  and  processing  of  cell 
populations, as well as the disease being targeted for treatment, are issues that should warrant 
further discussion.  
 
Beyond professional guidelines, greater consistency and less ambiguity in regulatory instruments 
across jurisdictions  is  necessary  because  even  though  they  provide regulators  with  a  degree of 
discretion,  the  vagaries  and  inconsistencies  are  also  open  to  willful  misinterpretation  and 
exploitation by unscrupulous operators. Relevant authorities should also activate existing laws and 
regulations  that  protect  consumers  from  false  advertising  and  the  provision  of  misleading 
information in medical practice. It is crucial that the wholesale marketing of such interventions 
without sufficient evidence should be prosecuted under the relevant consumer protection laws and 
offending practitioners sanctioned by the responsible medical authority. For clinical practice cannot 
be regulated in the same way as research if the goal is to ensure that patients have access to novel 
interventions where efficacy is uncertain and that innovation can occur within clinical contexts.  
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